Related Experiment Video
Updated: Feb 11, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
Published on: August 27, 2013
Iodine-125 seed brachytherapy inhibits non-small cell lung cancer by suppressing epithelial-mesenchymal transition
Yana He1, Liang Li2, Jihua Liu3
1Department of Medical Imaging, Second Hospital of Tianjin Medical University, Tianjin, China; Department of Medical Imaging, The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Purpose:
Metastatic non-small cell lung cancer (NSCLC) has posed a great clinical challenge with high mortality. Iodine-125 (I-125) seed brachytherapy has not been widely applied in clinic against NSCLC.
Methods And Materials:
Mice were injected with human H23 NSCLC cells to establish a mouse xenograft model, which received I-125 seed implantation. The curative effect, pathological impairments, and survival rate of mice were investigated. Changes in the expression levels of epithelial-mesenchymal transition (EMT) markers, including N-cadherin, E-cadherin, and vimentin, in the xenograft tumors were analyzed using reverse transcription polymerase chain reaction and Western blot.
Results:
The tumor volume and pathological effect were reduced by I-125 seed implant. I-125 seed implant also significantly improved survival rate of the model mice. Expression patterns of N-cadherin, E-cadherin, and vimentin were reversed in I-125 seed-implanted mice in comparison with control mice, indicating suppressed EMT.
Conclusions:
I-125 seed brachytherapy significantly inhibits NSCLC by suppressing EMT in a mouse model.
Insights
Iodine-125 (I-125) seed brachytherapy effectively treats non-small cell lung cancer (NSCLC) in mice. This treatment reduced tumors and improved survival by suppressing epithelial-mesenchymal transition (EMT).
Area of Science:
- Oncology
- Radiotherapy
- Molecular Biology
Background:
- Metastatic non-small cell lung cancer (NSCLC) presents a significant clinical challenge due to high mortality rates.
- Iodine-125 (I-125) seed brachytherapy is an underutilized treatment modality for NSCLC.
Purpose of the Study:
- To evaluate the efficacy of Iodine-125 (I-125) seed brachytherapy in a mouse model of non-small cell lung cancer (NSCLC).
- To investigate the impact of I-125 seed brachytherapy on tumor progression, pathological changes, and survival rates.
- To analyze the effect of I-125 seed brachytherapy on epithelial-mesenchymal transition (EMT) markers in NSCLC xenografts.
Main Methods:
- A mouse xenograft model was established using human H23 NSCLC cells.
- Mice underwent I-125 seed implantation for brachytherapy treatment.
- Tumor volume, pathological impairments, and survival rates were assessed.
- Expression levels of EMT markers (N-cadherin, E-cadherin, vimentin) were analyzed via RT-PCR and Western blot.
Main Results:
- I-125 seed implantation significantly reduced tumor volume and pathological effects.
- The treatment markedly improved the survival rate of the NSCLC model mice.
- Expression patterns of N-cadherin, E-cadherin, and vimentin were reversed, indicating suppressed EMT.
Conclusions:
- I-125 seed brachytherapy demonstrates significant inhibitory effects against non-small cell lung cancer (NSCLC).
- The therapeutic mechanism involves the suppression of epithelial-mesenchymal transition (EMT).
- These findings support the potential of I-125 seed brachytherapy as a viable treatment for NSCLC.
Related Concept Videos
Phase Transitions
Mesenchymal Stem Cells
Feedback Inhibition
Properties of Transition Metals
Cooperative Allosteric Transitions
Seed Structure and Early Development of the Sporophyte

